- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07797088
Assessment of Six-minute Walking Distance Between Sea Level LA vs. High Altitude HA After Re-ascent in Healthy Individuals
August 27, 2026 updated by: Silvia Ulrich Somaini
Effect of a One-week Descent From 2850m to Sea Level and Re-ascent in Patients With Pulmonary Arterial Hypertension and Healthy Controls Permanently Living > 2600m on Pulmonary Hemodynamics, Exercise Capacity, Blood Oxygenation, Sleep Disordered Breathing and Further Outcomes
To study the effect of a re-ascent after a one-week stay at sea level (after prior descent from 2850m) to high altitude (Quito Ecuador: 2850m) on six-minute walking distance and other scores in healthy individuals, who live permanently >2600m.
Study Overview
Status
Not yet recruiting
Intervention / Treatment
Detailed Description
The aim of this research is to investigate the six-minute walking distance and other scores before and after re-ascent (sea level for 7 days vs. re-ascent to 2850m) in healthy individuals, who permanently live at high altitude over 2600m.
Study Type
Interventional
Enrollment (Estimated)
14
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Silvia Ulrich, Prof. Dr. med.
- Phone Number: +41442552220
- Email: silvia.ulrich@usz.ch
Study Contact Backup
- Name: Michael Furian, Prof. Dr. sc. ETH
- Phone Number: +41442552220
Study Locations
-
-
-
Zurich, Switzerland
- University Hospital of Zurich
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Adults aged 18-80 years and of all genders
- Permanent residence > 2600 m
- healthy: no self-perceived cardiopulmonary disease limiting daily activities
- written informed consent to participate in the study.
Exclusion Criteria:
- Age <18 years or >80 years
- Participants who cannot follow the study investigations
- Participants permanently living < 2600m
- Participants who traveled and stayed overnight at altitudes <2000 m in the past 4 weeks.
- any self-perceived cardiopulmonary disease limiting daily activities
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: SIx-minute walking distance 6MWD after re-ascent at 2850m
Assessment of six-minute walking distance 6MWD and other scores after 7 days at sea level with re-ascent from sea level back to 2850m by bus (in one day) and assessments of the same outcomes
|
After 7 days at sea level return/re-ascent to their usual living altitude at 2850m
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Six-minute walking distance after re-ascent to 2850m
Time Frame: From Day 5-7 at sea level to the day after re-ascent
|
Difference/change in six-minute walking distance 6MWD between sea level (after one-week stay) and day after re-ascent at 2850m in healthy individuals
|
From Day 5-7 at sea level to the day after re-ascent
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
SpO2 at rest and end-exercise after re-ascent to 2850m
Time Frame: From Day 5-7 at sea level to the day after re-ascent
|
Difference/change in SpO2 (peripheral oxygen saturation) at rest and end-exercise between sea level (after one-week stay) and Day after re-ascent to 2850m in healthy individuals
|
From Day 5-7 at sea level to the day after re-ascent
|
|
Heart rate at rest and end-exercise after re-ascent to 2850m
Time Frame: From Day 5-7 at sea level to the day after re-ascent
|
Difference/change in heart rate at rest and end-exercise between sea level (after one-week stay) and Day after re-ascent to 2850m in healthy individuals
|
From Day 5-7 at sea level to the day after re-ascent
|
|
Blood pressure at rest and end-exercise after re-ascent to 2850m
Time Frame: From Day 5-7 at sea level to the day after re-ascent
|
Difference/change in blood pressure at rest and end-exercise between sea level (after one-week stay) and Day after re-ascent to 2850m in healthy individuals
|
From Day 5-7 at sea level to the day after re-ascent
|
|
Dyspnea and leg discomfort sensation after re-ascent to 2850m
Time Frame: From Day 5-7 at sea level to the day after re-ascent
|
Difference/change in dyspnea and leg discomfort sensation (assessed with BORG-CR10-Scale, Category Rating 0-10 with 10 being the most dyspnea/leg discomfort) at rest and end-exercise between sea level (after one-week stay) and day after re-ascent to 2850m in healthy individuals
|
From Day 5-7 at sea level to the day after re-ascent
|
|
NYHA functional class after re-ascent to 2850m
Time Frame: From Day 5-7 at sea level to the day after re-ascent
|
Difference/change in NYHA functional class (New York Heart Association Class I-IV, IV being the worst) at rest and end-exercise between sea level (after one-week stay) and day after re-ascent to 2850m in healthy individuals
|
From Day 5-7 at sea level to the day after re-ascent
|
|
Quality of life after re-ascent to 2850m
Time Frame: From Day 5-7 at sea level to the day after re-ascent
|
Difference/change in quality of life score (EmPHasis-10: Score with 10 questions and 0-50 points, higher scores indicating poorer quality of life) between sea level (after one-week stay) and day after re-ascent to 2850m in healthy individuals
|
From Day 5-7 at sea level to the day after re-ascent
|
|
General well-being after re-ascent to 2850m
Time Frame: From Day 5-7 at sea level to the day after re-ascent
|
Difference/change in general well-being (Visual Analog Scale 10cm: the higher, the worse) between sea level (after one-week stay) and day after re-ascent to 2850m in healthy individuals
|
From Day 5-7 at sea level to the day after re-ascent
|
|
Six-minute walking test pre-descent to after re-ascent
Time Frame: Baseline at 2850m followed by a one-week stay at sea level to the day after re-ascent back to 2850m (time frame approximately 11 days)
|
Difference/change in six-minute walking distance (6MWD) at 2850m with a one-week stay at sea level in between (day pre-descent vs. day after re-ascent) in healthy individuals
|
Baseline at 2850m followed by a one-week stay at sea level to the day after re-ascent back to 2850m (time frame approximately 11 days)
|
|
SpO2 at rest and end-exercise pre-descent to after re-ascent
Time Frame: Baseline at 2850m followed by a one-week stay at sea level to the day after re-ascent back to 2850m (time frame approximately 11 days)
|
Difference/change in SpO2 (peripheral oxygen saturation) at rest and end-exercise with a one-week stay at sea level in between (day pre-descent vs. day after re-ascent) in healthy individuals
|
Baseline at 2850m followed by a one-week stay at sea level to the day after re-ascent back to 2850m (time frame approximately 11 days)
|
|
Heart rate at rest and end-exercise pre-descent to after re-ascent
Time Frame: Baseline at 2850m followed by a one-week stay at sea level to the day after re-ascent back to 2850m (time frame approximately 11 days)
|
Difference/change in heart rate at rest and end-exercise with a one-week stay at sea level in between (day pre-descent vs. day after re-ascent) in healthy individuals
|
Baseline at 2850m followed by a one-week stay at sea level to the day after re-ascent back to 2850m (time frame approximately 11 days)
|
|
Blood pressure at rest and end-exercise pre-descent to after re-ascent
Time Frame: Baseline at 2850m followed by a one-week stay at sea level to the day after re-ascent back to 2850m (time frame approximately 11 days)
|
Difference/change in blood pressure at rest and end-exercise with a one-week stay at sea level in between (day pre-descent vs. day after re-ascent) in healthy individuals
|
Baseline at 2850m followed by a one-week stay at sea level to the day after re-ascent back to 2850m (time frame approximately 11 days)
|
|
Dyspnea and leg discomfort pre-descent to after re-ascent
Time Frame: Baseline at 2850m followed by a one-week stay at sea level to the day after re-ascent back to 2850m (time frame approximately 11 days)
|
Difference/change in dyspnea and leg discomfort (assessed with BORG-CR10-Scale, Category Rating 0-10 with 10 being the most dyspnea/leg discomfort) at rest and end-exercise with a one-week stay at sea level in between (day pre-descent vs. day after re-ascent) in healthy individuals
|
Baseline at 2850m followed by a one-week stay at sea level to the day after re-ascent back to 2850m (time frame approximately 11 days)
|
|
NYHA functional class pre-descent to after re-ascent
Time Frame: Baseline at 2850m followed by a one-week stay at sea level to the day after re-ascent back to 2850m (time frame approximately 11 days)
|
Difference/change in NYHA functional class (New York Heart Association Class I-IV, IV being the worst) at 2850m with a one-week stay at sea level in between (day pre-descent vs. day after re-ascent) in healthy individuals
|
Baseline at 2850m followed by a one-week stay at sea level to the day after re-ascent back to 2850m (time frame approximately 11 days)
|
|
Quality of life pre-descent to after re-ascent
Time Frame: Baseline at 2850m followed by a one-week stay at sea level to the day after re-ascent back to 2850m (time frame approximately 11 days)
|
Difference/change in quality of life (EmPHasis-10: Score with 10 questions and 0-50 points, higher scores indicating poorer quality of life) with a one-week stay at sea level in between (day pre-descent vs. day after re-ascent) in healthy individuals
|
Baseline at 2850m followed by a one-week stay at sea level to the day after re-ascent back to 2850m (time frame approximately 11 days)
|
|
General well-being pre-descent to after re-ascent
Time Frame: Baseline at 2850m followed by a one-week stay at sea level to the day after re-ascent back to 2850m (time frame approximately 11 days)
|
Difference/change in general well-being (Visual Analog Scale 10cm: the higher, the worse) with a one-week stay at sea level in between (day pre-descent vs. day after re-ascent) in healthy individuals
|
Baseline at 2850m followed by a one-week stay at sea level to the day after re-ascent back to 2850m (time frame approximately 11 days)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Silvia Ulrich, University Hospital Zurich, Departement of Pulmonology
- Principal Investigator: Rodrigo Hoyos, Hospital Carlos Andrade Marin of Quito, Ecuador
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
September 25, 2026
Primary Completion (Estimated)
October 4, 2026
Study Completion (Estimated)
December 31, 2026
Study Registration Dates
First Submitted
August 17, 2026
First Submitted That Met QC Criteria
August 27, 2026
First Posted (Actual)
September 1, 2026
Study Record Updates
Last Update Posted (Actual)
September 1, 2026
Last Update Submitted That Met QC Criteria
August 27, 2026
Last Verified
August 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Ec_LAvsHA_6MWD_H
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Data will be provided upon request and based on a clear intention reviewed by an ethical review board.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.